Tyrosine kinase receptors represent targets of great interest for cancer therapy. Here we show, for the first time, the importance of the orphan tyrosine kinase receptor, ROR2, in melanoma progression. Using melanoma tissue microarrays, we show that ROR2 is expressed predominantly in metastatic melanoma. As ROR2 has been shown to specifically interact with the non-canonical Wnt ligand, Wnt5A, this corroborates our earlier data implicating Wnt5A as a mediator of melanoma metastasis. We show here that increases in Wnt5A cause increases in ROR2 expression, as well as the PKC-dependent, clathrin-mediated internalization of ROR2. WNT5A knockdown by siRNA decreases ROR2 expression, but silencing of ROR2 has no effect on WNT5A levels. ROR2 knockdown does, however, result in a decrease in signaling downstream of Wnt5A. Using in vitro and in vivo metastasis assays, we show that ROR2 is necessary for the Wnt5A-mediated metastasis of melanoma cells. These data imply that ROR2 may represent a novel target for melanoma therapy.
Introduction
Wnt5A regulates melanoma progression, and its pattern of expression can differentiate between melanomas of different invasive capacity (Bittner et al., 2000; Weeraratna et al., 2002; Da Forno et al., 2008) . We have shown that Wnt5A mediates its effects through PKC and the downregulation of metastasis suppressors such as Kiss-1, the upregulation of metastasis-associated molecules such as CD44, and the initiation of an epithelial to mesenchymal transition (Dissanayake et al., 2007) . Recently, we have shown that Wnt5A can suppress the expression of tumor-associated antigens such as MART1, and gp100, making melanoma cells less susceptible to T-cell-mediated cytolysis (Dissanayake et al., 2008) .
The orphan tyrosine kinase receptor, ROR2 mediates non-canonical Wnt signaling (Saldanha et al., 1998; Oishi et al., 2003; Katoh, 2005) . ROR2 is a transmembrane receptor (Masiakowski and Carroll, 1992 ) that consists of a region of 10 cysteines, earlier identified as a Wnt-binding domain (Saldanha et al., 1998) . Mutations in ROR2 cause diseases such as brachydactyly type B and autosomal recessive Robinow syndrome, a severe skeletal dysplasia (Afzal et al., 2000; van Bokhoven et al., 2000) . Wnt5A requires ROR2 expression to mediate the migration of cells during mammalian palate development (He et al., 2008) , and for the formation of filopodia in mouse embryonic fibroblasts, a process that requires filamin A expression (Nishita et al., 2006) . We have recently shown that in melanoma cells, Wnt5A can increase the expression and calpain-mediated cleavage of filamin A, leading to increased melanoma cell motility (O'Connell et al., 2009a) . Here, we investigate the expression and function of ROR2 in melanoma and its relationship to Wnt5A expression.
Results
ROR2 expression correlates with levels of Wnt5A expression in human melanoma ROR2 expression was examined across a human melanoma tissue microarray (NCI Tissue Array Research Program, Bethesda, MD, USA). Wnt5A expression is stronger in metastatic tissues, although it is also present in a heterogenous manner in primary tumors (Dissanayake et al., 2008) . Our results show that ROR2 expression was absent in 28/48 primary melanomas (Figure 1a ), weakly positive in the cytoplasm in 14 (1 þ ) samples and strongly positive in 6 samples (2-3 þ ). Four out of 31 lymph node metastases were negative for ROR2, 16 were weakly positive, and 11 were positive. The pattern was most dramatic in other types of metastatic melanoma (comprised of both subcutaneous metastases and visceral metastases), as we have earlier noted with Wnt5A (Dissanayake et al., 2008) . In ROR2 positive visceral metastases (Figure 1b) , staining appeared to be both cytoplasmic and could also be found in the nuclear or perinuclear region (Figure 1b, arrow) . In the positive lymph node metastases, the location of ROR2 was largely at the membrane of the cells (Figure 1c , arrows). There were no visceral or subcutaneous metastases that were negative for ROR2, only 4 that were weakly positive, and the remaining 44 were strongly positive. These values are expressed as percentages in Figure 1d . w 2 analysis shows that ROR2 expression is significantly increased in metastatic melanoma (Po0.001).
To study the effects of ROR2 in melanoma, we selected four earlier characterized melanoma cell lines (Dissanayake et al., 2007 (Dissanayake et al., , 2008 . These include two less metastatic, Wnt5A-low cell lines, UACC1273EV and G361, and two more metastatic, Wnt5A-high cell lines, UACC903 and M93-047. ROR2 mRNA was highly expressed in the Wnt5A-high lines (UACC903 and M93-047) but not in the Wnt5A-low (G361 and UAC-C1273EV) melanoma lines (Figure 2a) , unlike FZD2 and FZD5, the expression of which does not correlate to that of Wnt5A (Supplementary Figure 1) . Western analysis also shows that ROR2 protein expression is higher in Wnt5A high lines, consistent with the data from the tissue microarray (Figure 2b ). Recombinant Wnt5A treatment resulted in an increase in ROR2 expression in the Wnt5A-low UACC1273EV cell line (Figure 2c ), as well as the G361 cell line (see Figure 2e) .
To examine the localization of ROR2 in these cells, we used immunofluorescent confocal microscopy. In the lowmetastatic, Wnt5A-low lines, ROR2 staining was of low intensity, and was dispersed throughout the cytoplasm in a diffuse granular pattern, with perinuclear and nuclear foci in o20% of the cells (Figure 2d , UACC1273EV and G361). Wnt5A-high lines also expressed ROR2 in a light, granular cytoplasmic pattern, but also had very intense staining in perinuclear foci in the majority of cells (Figure 2d, , reflective of the tissue array staining. To ensure that this focal localization of ROR2 was Wnt5A-dependent, and not cell line specific, Wnt5A-low G361 and UACC1273EV cells were treated with recombinant Wnt5A (rWnt5A) for 16 h. RWnt5A treatment resulted in an increase in the intensity of ROR2 along with the shift of ROR2 from a diffuse cytoplasmic distribution to perinuclear and nuclear foci (Figure 2e ). We suspected that these results might be due to rapid internalization of ROR2 on ligand binding, which would explain why cells that have high Wnt5A also have perinuclear and nuclear localization of ROR2. To determine whether ROR2 and Wnt5A could both be found in these internal foci, Wnt5A-high cells were stained with ROR2 and Wnt5A. ROR2 and Wnt5A co-localize in the Figure 1 ROR2 expression in human melanoma. Staining of a melanoma tissue microarray shows that the majority of primary melanomas do not express ROR2 (a), whereas subcutaneous or visceral metastases of melanoma stained very strongly for ROR2 in the cytoplasm and nucleus (b, arrows show nuclear staining). Lymph node metastases for the most part had very light staining of ROR2, and in these specimens ROR2 appeared to be largely at the membrane of the cell (c, arrows). Overall staining results are represented as percentage of samples positive per group (d). The increase in ROR2 expression in metastatic melanoma as compared with primary melanoma is significant to Po0.0001.
ROR2 mediates Wnt5A signaling in metastatic melanoma MP O'Connell et al observed foci (Figure 2f ), but it is unclear whether this is a physical interaction.
ROR2 is internalized through clathrin, in a PKC-dependent manner The perinuclear localization of Wnt5A/ROR2 was consistent with reports that Wnt signaling can occur from within endosomal compartments (Blitzer and Nusse, 2006) . Neurotrophic tyrosine kinase receptors, to which ROR2 bears significant homology, have also been shown to signal from within endosomes on ligand binding (Howe et al., 2001) . This requires internalization through clathrin, and ligand-bound Trk receptors are often found in clathrin-coated endosomes in neuronal cells. Immunofluorescent analyses showed that ROR2 (green) co-localized with clathrin (red) in Wnt5A high cell lines (Figure 3a ), but not caveolin (Supplementary 2 ROR2 expression and localization in human melanoma cell lines. ROR2 mRNA is highly expressed in Wnt5A high lines (UACC903 and M93-047), but not Wnt5A low UACC1273EV and G361 cells (a). ROR2 protein levels are also higher in Wnt5A high lines than Wnt5A-low G361 cells, as shown by western analysis (b). Treating ROR2-low UACC1273EV cells with rWnt5A increases ROR2 expression (c). Immunofluorescent analysis shows that in Wnt5A-low lines, ROR2 is expressed in a diffuse cytoplasmic pattern in most cells. In Wnt5A-high lines, ROR2 is expressed in both a diffuse pattern as well as in perinuclear/nuclear foci in the majority of the cells (d). Treatment of Wnt5A-low cells with rWnt5A increases the focal localization of ROR2 (e). Wnt5A and ROR2 expression are both expressed in the perinuclear foci, as shown by immunolocalization analysis (f). Figure 2A ). In Wnt5A high cells, ROR2 also co-stains with both EEA1, a marker of the early endosome (Supplementary Figure 2B) , supporting the theory that ROR2 is being internalized into endosomes. To determine whether Wnt5A causes clathrin-mediated internalization of ROR2, cells were treated with rWnt5A. Indeed, after only 5 min of treatment with Wnt5A, ROR2 is internalized into foci, and colocalizes with clathrin ( Figure 3b ). To determine whether clathrin was required for ROR2 internalization, we inhibited clathrin using monodansylcadaverine (MDC). On treatment of cells with 50 mM of MDC for 1 h, ROR2 internalization was inhibited in the majority of cells (Figure 3c , arrows). To show that clathrin-mediated receptor internalization is important for melanoma cell invasion, we treated cells with MDC (50 mM for 1 h), and subjected them to an invasion assay. Cells treated with MDC were unable to invade through Matrigel at the same rate as the untreated cells (Figure 3d ). For an even more specific approach, we transfected cells with Clathrin 1 siRNA, which knocked down a large portion of the clathrin in the cell (Figure 3e ), after which a wound-healing assay was performed. Cells treated with Clathrin 1 siRNA were also unable to close a wound as fast as those transfected with a control siRNA (Figure 3f ), indicating the importance of Clathrin in melanoma motility.
Wnt5A acts through the release of intracellular calcium and the activation of PKC, and resulting in a positive feedback loop, in which increased PKC can increase Wnt5A expression and signaling. ROR2 can be phosphorylated at serine and threonine residues on Wnt5A treatment (Yamamoto et al., 2007) , but it is unclear whether PKC can phosphorylate ROR2, or affect its expression or subcellular localization. We Figure 3 ROR2 is internalized through clathrin in a PKC-dependent manner. Immunofluorescent analysis indicates that ROR2 (green) co-localizes with clathrin (red, a, arrows). Wnt5A treatment causes an immediate internalization of ROR2 and co-localization of ROR2 and clathrin (b). Monodansylcadaverine (MDC) inhibits the internalization of ROR2 through clathrin and causes its redistribution from foci to the periphery of the cell (c, arrows). MDC inhibition also decreases the invasion of melanoma cells through Matrigel (d). Clathrin siRNA decreases clathrin expression as shown by western blot analysis (e) and decreased clathrin inhibits the motility of melanoma cells as shown in a wound-healing assay (f). In Wnt5A-high cells, PKC inhibition results in the movement of ROR2 (green) from foci to a diffuse cytoplasmic distribution in cells, on PKC inhibition (g). Foci reappear at 6 h after treatment. Costaining with clathrin (red) indicates that PKC inhibition may affect ROR2 internalization, as in the presence of PKC inhibitor, ROR2 does not co-localize with clathrin (h). Re-emergence of ROR2-positive foci at 6 h of PKC inhibitor treatment corresponds to increased co-localization with the golgi (i, arrows).
have shown earlier that the PKC inhibitor GÖ 6983 can inhibit Wnt5A signaling and melanoma cell motility (Dissanayake et al., 2007; O'Connell et al., 2008) . To ascertain whether ROR2 internalization could be affected by PKC inhibition in Wnt5A-high cells, cells were treated with GÖ 6983, resulting in a redistribution of ROR2 from its perinuclear foci to the cytoplasm, beginning as early as 5 min (Figure 3g) . By 6 h of GÖ 6983 treatment, foci reappeared, and there was also an increase in ROR2 expression. To determine whether PKC activity was necessary for the internalization of ROR2 through clathrin, Wnt5A-high cells were treated with GÖ 6983 and then stained for the co-expression of ROR2 and clathrin. (Figure 3h ). In the presence of GÖ 6983, ROR2 did not co-localize with clathrin, and this separation could be observed after 5 min of PKC inhibition. ROR2 and clathrin remained separate at 6 h of treatment, despite the re-emergence of ROR2 positive foci. We hypothesized that the increased expression and focal redistribution of ROR2 might correspond to an increase in ROR2 synthesis and secretion, in response to PKC inhibition, as part of an initial signaling feedback loop. To confirm this, we stained cells for the co-expression of ROR2 and golgin (Figure 3i ). At 5 min of PKC inhibition, there was no association between the cytoplasmic ROR2 and the golgi. However, unlike clathrin, at 6 h there was a re-association of ROR2 with the golgi (Figure 3i , arrows), indicative of increased processing and secretion of the protein. These data imply that the activation of PKC by Wnt5A/ROR2 results in a phosphorylation of the ROR2 receptor, or some other intermediate, which in turn results in the clathrin-mediated internalization of ROR2.
Wnt5A affects ROR2 expression and requires ROR2 for signaling To further explore the relationship between Wnt5A and ROR2, we assessed whether knockdown of WNT5A affected levels of ROR2 expression. Cells were treated with siRNA against WNT5A for 24, 48, and 72 h, after which time ROR2 mRNA was analyzed by real-time PCR (Figure 4a) . At 72 h after the knockdown of WNT5A mRNA, ROR2 mRNA expression was dramatically decreased (Figure 4a ). This was concomitant with the maximal decrease in Wnt5A protein at 72 h (Figure 4a, inset) . Immunofluorescent analysis showed that ROR2 protein levels were also reduced after Figure 4 Wnt5A expression modulates ROR2 expression, and requires ROR2 for signaling. WNT5A knockdown results in a decrease in ROR2 mRNA (a, solid lines) in both UACC903 and M93-047 cells as analyzed by real-time PCR (a) and in ROR2 protein as analyzed by immunofluorescence (b). Wnt5A protein is maximally decreased at 72 h, coincident with the greatest levels of ROR2 knockdown (a, inset). ROR2 knockdown results in a decrease in ROR2 mRNA (c) and protein (d), but not WNT5A mRNA (c, dashed lines). However, ROR2 knockdown does inhibit Wnt5A signaling as shown by a decrease in PO 4 -PKC (e) and an increase in MART-1 expression by western analysis (f).
WNT5A siRNA treatment (Figure 4b ). To determine whether ROR2 modulation could affect WNT5A expression, Wnt5A-high cells were treated with ROR2 siRNA, which was maximally reduced in UACC903 cells by 72 h and M93-047 cells by 48 h (Figure 4c ). ROR2 protein is also reduced post-siRNA treatment (Figure 4d ). However, in these Wnt5A-high cells, WNT5A expression is not greatly affected by ROR2 knockdown (Figure 4c, dashed lines) . Although WNT5A expression was not regulated by knockdown of ROR2, Wnt5A signaling was markedly attenuated on the lowering of ROR2 levels. This was shown by decreases in the levels of PO 4 -PKC (Figure 4e) , and by increases in levels of proteins that we have shown to be suppressed by Wnt5A (Dissanayake et al., 2008) such as MART1 (Figure 4f ). These data show that WNT5A expression governs that of ROR2, and while ROR2 downregulation cannot affect WNT5A expression, it can affect the downstream signal transduction from this ligand.
Reduction of ROR2 results in a decrease in the invasion and metastasis of melanoma cells
We have shown earlier that rWnt5A can increase the metastasis of melanoma cells in an in vivo assay (Dissanayake et al., 2008) . In that experiment, we used the well-accepted melanoma metastasis model of B16F10 melanoma cells, which form pulmonary metastases on tail vein injection. These cells have low levels of Wnt5A, but treatment with rWnt5A can further increase the levels of Wnt5A that they produce ( Supplementary  Figure 4) , and activate Wnt5A-mediated signaling (Dissanayake et al., 2008) . In an earlier study, to see the metastasis-promoting effects of Wnt5A, we reduced both the number of cells injected into the mice (2 Â 10 5 ), and the time for development of metastases (B2 weeks). This resulted in very few control mice presenting with pulmonary metastases. However, rWnt5A treatment dramatically increased both the incidence and number of metastases (Dissanayake et al., 2008) .
In B16 cells, Ror2 is largely cytoplasmic, but treatment of these cells with rWnt5A dramatically increased the number of foci (Figure 5a, þ rWnt5A) . We used mouse Ror2 siRNA to knockdown Ror2 expression, and confirmed its effectiveness (Figure 5a , Ror2 siRNA). Earlier in vivo studies have indicated the effective use of naked duplex siRNAs in vivo. Lewis et al. (2002) have shown that siRNA duplexes can be injected i.v. into animals and detected within 24 h of injection in organs such as liver, lung kidney, and spleen. Other experiments have shown that even single-dose i.v. injections of siRNA duplexes can be effective over a period of as long as 10 days, in diseases such as autoimmune hepatitis (Song et al., 2003) . Liang et al. (2005) have shown that it is possible to use naked siRNA duplexes in vivo to inhibit cancer metastasis, and that this is most effective when siRNA is systemically re-administered every 48-72 h. Following this protocol, we treated B16 cells with control or Ror2 siRNA, and Ror2 siRNA-treated cells were then treated with either rWnt5A or vehicle controls. To determine whether Ror2 knockdown could decrease pulmonary metastases, we attempted to maximize the amount of metastases, by injecting the mice with 1 Â 10 6 cells, which were injected through the tail vein, into 10 mice per group. Twice a week, rWnt5A-treated mice received booster injections of rWnt5A. In addition, mice injected with siRNA-transfected cells received booster injections of siRNA (that is all mice received either control siRNA or Ror2 siRNA injections) according to the protocol of Liang et al. (2005) . Eight out of nine mice injected with control siRNA developed pulmonary metastases. In contrast, only 3 out of 10 mice treated with Ror2 siRNA developed metastases (Po0.02), and rWnt5A treatment could not significantly increase pulmonary metastases in these mice (4/10 mice developed metastases). Representative lung metastases are shown in Figure 5b . Immunohistochemistry revealed that Ror2 siRNA-treated mice had very low levels of microscopic metastases. These data imply that fewer Ror2 negative cells either reach or survive at the sites of extravasation, and only a subset of those have the propensity to establish tumorigenic colonies (Figure 5c ).
To determine whether ROR2 is important in Wnt5A-mediated invasion in human melanoma cells as well, a Matrigel invasion assay was performed after 48 h of ROR2 siRNA treatment in Wnt5A-high cell lines (UACC903 and M93-047). ROR2 siRNA inhibits migration of these highly metastatic melanoma cells through Matrigel by over 50% (Figure 6a) . Further, treatment of G361 melanoma cells with rWnt5A in the presence of control siRNA increased their invasion through Matrigel, but in the presence of ROR2 siRNA, rWnt5A was unable to increase migration (Figure 6b) . ROR2 siRNA appears to have little effect by itself, but this is likely due to the fact that G361 cells are so nonmetastatic, there is already minimal invasion through Matrigel (Supplementary Figure 3A) . We also performed wound-healing assays that supported these observations (Supplementary Figure 3B-D) .
Finally, to determine whether ROR2 inhibition could regulate the metastasis of human melanoma cells in vivo, M93-047 melanoma cells were injected through the tail vein of nude mice. Cells were either transfected with a control siRNA or with ROR2 siRNA for 48 h before injection. As in the earlier described B16 model, mice were injected with control or ROR2 siRNA bi-weekly. Of the five mice injected with M93-047 cells treated with control siRNA, four had tumors that were macroscopically visible (Figure 6c ). All had several microscopically visible tumors, usually surrounded by areas of massive hemorrhage (Figure 6c , Mouse 3, CTRL SIRNA arrows). Only one of the ROR2 siRNA-treated mice had macroscopically visible tumors. The rest of the ROR2 siRNA-treated mice did not have any evidence of tumor spread, and very few micrometastases. Three representative mouse lungs from each group are shown in Figure 6c , two macroscopically, one microscopically. These data support our B16 mouse model, and confirm that ROR2 may indeed mediate melanoma metastasis.
Discussion
In this study we have characterized, for the first time, the expression and function of ROR2 in melanoma, which bears significant homology to neurotrophic tyrosine kinase receptors (specifically NTRK2). The increased expression of neurotrophic tyrosine kinase receptors has been shown earlier to correlate to increased aggression in many types of cancer (Weeraratna et al., 2001; Desmet and Peeper, 2006) and may provide specific targets for cancer therapy (Weeraratna et al., 2000) . Our study shows that ROR2 is an important mediator of Figure 5 ROR2 knockdown inhibits the in vivo invasion of melanoma cells in a murine model. B16 melanoma cells express the Ror2 receptor in a pattern, and at levels similar to that of UACC1273EV cells (a, CTRL). Treatment of B16 cells with rWnt5A causes redistribution of Ror2 to perinuclear foci, as seen with human cells (a, CTRL þ rWnt5A). Treating B16 cells with Ror2 siRNA results in a decrease in Ror2 expression (a, Ror2 siRNA). in vivo tail vein metastasis assays show that Ror2 knockdown can significantly inhibit the pulmonary metastasis of melanoma cells, an effect that cannot be recovered by the addition of rWnt5A (b). Outliers in each group are shown and underlined. Immunohistochemical analysis of these tumors indicates that there are very few micrometastases in the ROR2 siRNA-treated mice (c).
Wnt5A-induced invasion in melanoma. Increases in Wnt5A increased ROR2 expression, and internalization, and reduction of WNT5A decreased ROR2 expression. However, reduction of ROR2 did not affect WNT5A levels, although it did inhibit Wnt5A signaling and both in vivo and in vitro metastasis. ROR2 is upregulated predominantly in metastatic tumors, and correlates to Wnt5A expression. A recent study confirmed that the expression of Wnt5A is strongly correlated to poorer survival in melanoma patients (Da Forno et al., 2008) . Our data suggest the same might be true for ROR2.
Wnt5A can act through the Frizzled family of receptors, and in humans Wnt5A binds to Fzd2 or Fzd5 to activate non-canonical signaling. We have shown earlier that inhibition of Fzd5 can inhibit melanoma cell motility, implicating this receptor in melanoma invasion (Weeraratna et al., 2002) . In rheumatoid arthritis, the inhibition of Fzd5 can also inhibit the Wnt5A-mediated migration of synovial fibroblasts (Sen et al., 2001) . Elegant work from the Andersson laboratory has shown that when using the hexapeptide Foxy-5, which is a Wnt5A derivative, Wnt5A effects can be mimicked in the presence of a Fzd2 antibody, but not a Fzd5 antibody, further highlighting the requirement for Fzd5 (Safholm et al., 2006 (Safholm et al., , 2008 . As we have shown here, ROR2 is also critically required for Wnt5A-mediated melanoma metastasis, just as it is for Wnt5A-induced, but not Wnt3A-induced, migration of osteoblasts (Nishita et al., 2006) . There are two important advantages of pursuing ROR2 as a molecular target over Fzd5 in melanoma. First, ROR2 is a Wnt5A-specific receptor (Nishita et al., 2006; Liu et al., 2008) that is not known to activate canonical Wnt signaling, unlike Fzd5, which has been shown to activate axis induction (b-catenin mediated) on Wnt5A binding (He et al., 1997) . Second, unlike Fzd5, which is expressed in the granular layer of normal skin (Romanowska et al., 2009) , and across all stages of melanoma (Supplementary Figure 1) , ROR2 is expressed increasingly during malignancy, allowing us to target the most aggressive cells, potentially without disrupting normal skin function.
We have also explored the significance of the subcellular localization of ROR2 in highly metastatic cells. It has been shown that canonical Wnt proteins such as Wingless are first secreted to the cell surface through the golgi, then compartmentalized into endosomes and recycled to the surface (Pfeiffer et al., 2002) . The localization of ROR2 is dependent on the amount of Wnt5A present: in the presence of high amounts of Wnt5A, there is more internalized ROR2. Our observations support data from other groups that show that ROR2 localizes to rab35 positive endosomes on phosphorylation (Akbarzadeh et al., 2008) . A recent study also shows that Wnt5A treatment can result in the phosphorylation of ROR2 on its serine and threonine residues (Yamamoto et al., 2007) . This is of particular interest as we have shown that, in melanoma, Wnt5A can act through PKC, a serine/threonine kinase. In the presence of PKC inhibitors, Wnt5A cannot mediate many of its effects nor modulate the invasive capacity of melanoma (Dissanayake et al., 2007) . Inhibiting PKC can inhibit the clathrin-mediated internalization of ROR2, suggesting that PKC-phosphorylation of ROR2 is necessary for its internalization and potentially, its downstream signaling. As receptors that are internalized through clathrin are often packaged into endosomes and recycled to the surface for increased signaling, our data indicate that ROR2 phosphorylation may be a pivotal step in the earlier described positive feedback loop between PKC and Wnt5A (Jonsson et al., 1998) .
Thus far, data from our laboratory indicates that Wnt5A expression is increased in more aggressive melanoma cells, and secreted by them (Dissanayake et al., 2007) . However, Wnt5A remains bound tightly to the surface of the melanoma cells by heparan sulfate proteoglycans (O'Connell et al., 2009b) , which we believe can present Wnt5A to its receptors, thereby increasing autocrine signaling. We have also shown that through PKC and STAT3, Wnt5A suppresses the expression of melanoma differentiation antigens, decreasing the immunogenicity of melanoma cells (Dissanayake et al., 2008) . Wnt5A causes an epithelial to mesenchymal transition, decreases the expression of metastasis suppressors such as kiss-1 (Dissanayake et al., 2007) and affects cytoskeletal proteins (O'Connell et al., 2009a) . In this study, we show that many of these effects likely depend on the expression of ROR2, as in its absence, melanoma differentiation antigen expression and PKC signaling are decreased (Figure 4) , as is melanoma metastasis. In conclusion, our findings suggest that Wnt5A and ROR2 act synergistically to increase metastatic potential in melanoma, making ROR2 an attractive molecular target for melanoma therapy.
Materials and methods
Cell culture UACC903, M93-047, and UACC1273EV were maintained in RPMI (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 100 units/ml penicillin and streptomycin and 4 mM L-glutamine. G-361 cells were maintained in McCoy's (Invitrogen) supplemented with 10% FBS, 100 units/ml penicillin and streptomycin and 4 mM L-glutamine. All cell lines were cultured at 37 1C in 5% CO 2 and the medium was replaced every 2 to 3 days. siRNA transfection HP-validated CTRL and ROR2 siRNA (200 nmoles, Qiagen, Valencia, CA, USA) were transfected into cells using Lipofectamine (Invitrogen) for 24, 48, and 72 h as described earlier . Sequences for siRNA were CTRL: sense-5 0 -UUCUCCGAACGUGUCGUCACGU-3 0 , antisense-5 0 -ACGUGACACGUUCGGAGAA-3 0 ; ROR2: sense-5 0 -GGUUUGGGAAAGUAUACAA-3 0 , antisense-5 0 -UUGUAGACUUUCCCAAACC-3 0 . A second siRNA to ROR2 was used to confirm specificity of the effects of ROR2 knockdown on migration (Supplementary Figure 3E and F) , and the sequence for this siRNA was ROR2 siRNA 2: Sense 5 0 -r(GGUGCUUUACGCAGAAUAATT)dTdT-3 0 Antisense 5 0 -r(UUAUUCUGCGUAAAGCACCAG)dGdG-3 0 .
Treatments
For recombinant Wnt5A treatment, 200 ng/ml of rWnt5A (R&D Systems, Minneapolis, MN, USA) was added for 16 h. For PKC inhibition experiments, GO6983 (Sigma, St Louis, MO, USA) was added to cells at a concentration of 1 mM for the indicated time. These concentrations and treatment times have been established earlier as optimal for these cells (Dissanayake et al., 2007) . For monodansylcadaverine (MDC) treatments, cells were treated with 50 mM MDC (Sigma) for 1 h.
Immunofluorescence Cells were seeded into one-well chamber slides (Nunc, Rochester, NY, USA) at 2 Â 10 5 cells/slide and incubated overnight. Cells were then fixed and blocked as described earlier . Primary antibodies used were ROR2 (1:100, Cell Signaling, Danvers, MA, USA), caveolin (1:100) and clathrin (1:100, BD Bioscience, Bedford, MA, USA), EEA1 (1:100, Abcam, Cambridge, MA, USA), and golgin-97 (1:100, Invitrogen). Primary antibodies were added in blocking buffer, and cells were incubated overnight at 4 1C. Cells were then washed in PBS and stained with the appropriate secondary antibody (1:2000, Alexa fluor-488 or Alexa fluor-555, Invitrogen). Cells were incubated for 1 h at room temperature and then washed in PBS and mounted in Prolong Gold anti fade reagent containing DAPI (Invitrogen).
Immunohistochemistry
Paraffin tissue sections were rehydrated through a xylene/ alcohol series, and antigen retrieval was performed as described earlier (Dissanayake et al., 2008) . Slides were then placed in primary antibody (ROR2, 1:10, Abgent, San Diego, CA, USA) and left at 4 1C overnight. Slides were washed in PBS (3 Â 5 min) and treated with anti-rabbit biotinylated HRP (1:500, Amersham Biosciences, Piscataway, NJ, USA) for 1 h. Slides were washed, developed using diamino-benzidine chromagen (Lab Vision, Fremont, CA, USA) and counterstained using hematoxylin, and then scored by a pathologist (SMH).
Real-time PCR RNA was extracted using Trizol (Invitrogen) and an RNeasy Mini kit (Qiagen) as described earlier . Gene expression was quantified using the SYBR green method of real-time PCR and mRNA levels were compared with standard curves. Primers were designed to cross intron exon junctions where possible: ROR2: forward-GGCAGAACCC ATCCTCGTG, reverse-CGACTGCGAATCCAGGACC; WNT5A: forward-TAAGCCCAGGAGTTGCTTTG, reverse-GCAGAGAGGCTGTGCTCCTA; FZD2: forward-ACATCGCCTACAACCAGACC, reverse-CCTTCACCAG
